<DOC>
	<DOCNO>NCT02578095</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , placebo-controlled , multicenter study investigate safety , tolerability , efficacy VK5211 12 week treatment . Males females ≥65 year old ambulatory recover hip fracture eligible participation 3-7 week post-injury .</brief_summary>
	<brief_title>Acute Hip Fracture Study Patients 65 Years Greater</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<criteria>Males female ≥65 year old recover hip fracture ( occur 37 week prior ) residual surgical issue eligible participation . Pathological fracture ( e.g . fracture due Paget 's disease bone , malignancy , etc. ) . Fracture due postmenopausal osteoporosis consider pathological trial .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>